Literature DB >> 9034237

Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model.

K A Stringer1, S K Bose, J M McCord.   

Abstract

Exogenous plasminogen activators (PAs), such as streptokinase (SK) and tissue plasminogen activator (tPA), have been shown to significantly improve the mortality of patients with acute myocardial infarction. However, reperfusion of the myocardium is associated with neutrophil activation and infiltration into the infarct region. Plasminogen activators influence neutrophil function in vitro, but no data exists regarding the effect of exogenous PAs on inflammation in vivo. Therefore, we evaluated the effect of PAs on inflammation using the carrageenan-induced rat footpad inflammation model. The magnitude of carrageenan-induced inflammation was determined by water-displacement and neutrophil infiltration, following administration of either tPA or SK to Sprague-Dawley rats. tPA (12 mg/kg) inhibited carrageenan-induced inflammation (p < .01). In contrast, administration of SK (40,000 U/kg) enhanced inflammation. These results suggest that exogenous PAs influence the inflammatory process but specific PAs differ in their actions. Ultimately, these differences may influence the efficacy of these agents in the management of acute myocardial infarction and lead to further evaluation of tPA in other inflammatory diseases such as acute respiratory distress syndrome (ARDS) and rheumatoid arthritis (RA), in which neutrophil-mediated injury is likely.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9034237     DOI: 10.1016/s0891-5849(96)00484-4

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  8 in total

Review 1.  Anticoagulant therapy in acute respiratory distress syndrome.

Authors:  Marta Camprubí-Rimblas; Neus Tantinyà; Josep Bringué; Raquel Guillamat-Prats; Antonio Artigas
Journal:  Ann Transl Med       Date:  2018-01

2.  Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis.

Authors:  Andrew D Cook; Emma L Braine; Ian K Campbell; John A Hamilton
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

3.  Accelerated dosing frequency of a pulmonary formulation of tissue plasminogen activator is well-tolerated in mice.

Authors:  Kathleen A Stringer; Meghan Tobias; John S Dunn; Jackie Campos; Zachary Van Rheen; Mitra Mosharraf; Rajiv Nayar
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-07-29       Impact factor: 2.557

Review 4.  Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome.

Authors:  Robert MacLaren; Kathleen A Stringer
Journal:  Pharmacotherapy       Date:  2007-06       Impact factor: 4.705

5.  Thrombus Degradation by Fibrinolytic Enzyme of Stenotrophomonas sp. Originated from Indonesian Soybean-Based Fermented Food on Wistar Rats.

Authors:  Florensia Nailufar; Raymond R Tjandrawinata; Maggy T Suhartono
Journal:  Adv Pharmacol Sci       Date:  2016-08-21

6.  Aptamer-Based Proteomics Identifies Mortality-Associated Serum Biomarkers in Dialysis-Dependent AKI Patients.

Authors:  Li-Rong Yu; Jinchun Sun; Jaclyn R Daniels; Zhijun Cao; Laura Schnackenberg; Devasmita Choudhury; Paul M Palevsky; Jennie Z Ma; Richard D Beger; Didier Portilla
Journal:  Kidney Int Rep       Date:  2018-05-03

7.  Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury.

Authors:  Cong Liu; Yana Ma; Zhenlei Su; Runzhen Zhao; Xiaoli Zhao; Hong-Guang Nie; Ping Xu; Lili Zhu; Mo Zhang; Xiumin Li; Xiaoju Zhang; Michael A Matthay; Hong-Long Ji
Journal:  Front Immunol       Date:  2018-08-20       Impact factor: 7.561

Review 8.  Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS.

Authors:  Shahideh Amini; Aysa Rezabakhsh; Javad Hashemi; Fatemeh Saghafi; Hossein Azizi; Antoni Sureda; Solomon Habtemariam; Hamid Reza Khayat Kashani; Zahra Hesari; Adeleh Sahebnasagh
Journal:  J Intensive Care       Date:  2022-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.